Molecular studies in recent years have highlighted various potential therapeutic targets in HCC, including VEGF and FGF, EGFR, HGFR/c-Met, IGFR, survivin, Wnt signaling, Src signaling, the Ras/Raf/p38 MAP kinase (MAPK) pathway, and the PI3K/AKT/mTOR pathway [6,8,9]. Here, MAPK14 is linked to hepatocellular carcinoma.